Journal of Advanced Zoology

ISSN: 0253-7214

*Volume **45** Issue **2 Year 2024** Page **1383-1388***

Precision Medicine In Acute Myeloid Leukaemia

Saptarshi Mukherjee[1], Sumit Nath[2], Santanu Paul[3]*

[1]Department of Bioinformatics , Maulana Abul Kalam Azad University of Technology , West Bengal , India
[2]Department of Biotechnology , Maulana Abul Kalam Azad University of Technology , West Bengal , India
[3]Associate Professor , Indian Institute of Science Education And Research , Tirupati , Andhra Pradesh , India*

***Corresponding Author :** Santanu Paul*
** Associate Professor , Indian Institute of Science Education And Research , Tirupati , Andhra Pradesh , India Email : Paulsantanu24@Gmail.Com*

Article History

Abstract

Precision medicine also known as personalised or individualised medicine is an innovative method that integrates genomic, environmental, and lifestyle data to drive medical care decisions. Precision medicine aims to give more precise approaches to illness prevention, diagnosis, and treatment. Precision medicine has revolutionized the treatment and diagnosis of acute myeloid leukaemia, which is mainly based on chemotherapy and personalised techniques according to the molecular and genetic profile and targeted therapy . For almost every kinds of AML chemotherapy is considered as the primary treatment, however it can also be utilised in other treatments. Acute promyelocytic leukaemia (APL) belongs to the sub category of acute myeloid leukaemia that receives distinct treatment. AML treatment should begin as soon as possible following diagnosis since it can progress rapidly. A mutation is present in the FLT3 gene of the Leukaemia cells. Some newer medications specifically target cells that have this gene alteration. FLT3 inhibitors like midostaurin (Rydapt), quizartinib (Vanflyta), and gilteritinib (Xospata) are now approved to treat patients with acute myeloid leukaemia cells that have a FLT3 mutation. The importance of understanding leukemogenesis at the molecular level through genetic sequencing has led in prognostic assessments and the use of targeted therapies. For the identification of the best treatments, mutation analysis using Next Generation Sequencing is essential.

Keywords: Acute myeloid leukaemia; targeted therapeutics medications; chromosome abnormalities.

Introduction

Precision medicine considers individual differences in genes, environment, and lifestyle for treating and preventing diseases[1]. This method, unlike one-size-fits-all therapy, enables physicians and researchers to better forecast which treatment and prevention strategies for a specific disease will be effective for distinct

patient populations. The complex biology of AML has been investigated by researchers over the past few decades, with a focus on how pre-treatment somatic mutations affect chemotherapy responses and AML pathogenesis. These developments have improved our understanding of leukemogenesis, enabling more accurate prognostic evaluation and survival-enhancing treatment adjustments[2],[3]. After thorough testing in clinical trials, small molecule inhibitors of pathogenic mutant proteins are now approved for use in the treatment of AML, either in isolation or in conjunction with chemotherapy. Acute myeloid leukaemia (AML) has a poor prognosis due to characteristics such as advanced age, high relapse rates, and resistance to conventional treatments. Personalized medicine, which modifies the treatment methods to each patient's specific characteristics like genetic mutations, chromosomal abnormalities and general health status, can play an important role in AML by improving outcomes[4],[5].

Risk factors associated with Acute Myeloid Leukaemia usually when age is above 65 years , habit of smoking , Previous treatment with certain forms of chemotherapy or radiation therapy , Previous history of blood disorders, such as myelodysplastic syndrome, myeloproliferative neoplasm, or aplastic anaemia , Some birth abnormalities and diseases, including Down syndrome , exposure to harmful chemicals[6].

A patient with acute myelogenous leukaemia may have a number of symptoms, including fever, dizziness, loss of appetite, feeling fullness or pain below the rib on either side, shortness of breath, night and headache, tiredness or weakness, unexplained weight loss, infections, easy bruising or bleeds[7].

Figure 1. Occurrence of different kinds of cells from Blood Stem Cells.



Clinical Presentation

With a median age of 68, AML is rarely diagnosed before the age of 45. Observed signs such as fever, weakness, infection, redness, and bleeding may manifest in cases. Further signs and effects could arise from the leukemic infiltration of the bone marrow impeding the formation of normal blood cells. Most cases show indications or symptoms of leukaemia cell buildup in specific anatomical sites, like the central nervous system (CNS) or the presence of a myeloid sarcoma (also called a chloroma). Acute leukaemia symptoms typically worsen over a 4- to 6-week period prior to diagnosis. New adverse prognostic variables for AML include the following:

• Opinion's age , adult AML absorption rates are age-related, so that those under 60 years old could expect an absorption rate higher than 65. Age appears to be a significant predictor of increased morbidity and death.
• CNS involvement in leukaemia.
• There is a systemic infection at the opinion.
• At the time of the examination, the white blood cell count was more than 100,000/mm3.
• Treatment-related myeloid tumours resulting from alkylating drugs and radiation therapy[8].

In the last six to seven years, oncologists treating acute myeloid leukaemia (AML) have made better decisions

based on their understanding of biomarkers such as inheritable lesions, mutations, and chromosome abnormalities and how they affect a case and lead to certain conditions. A medicine called uproleselan has been developed to target the selectin ligand commerce.

The treatment of acute myeloid leukaemia (AML) is often separated into two major periods.

• Absolution (also known as induction)

• Connection (a post-remission cure) Following connection, a third phase termed as conservation is used on occasion. Treatment for AML should begin immediately following diagnosis since it can progress extremely quickly. Before the chemotherapy can take effect, there may be a need for another kind of treatment[9].

Treatment of Leukostasis

When AML patients are first diagnosed, their blood may have abnormally high concentrations of leukaemia cells, which could interfere with normal blood rotation. Leukostasis is the term used for this. Chemotherapy can take many days to decrease the bloodstream's leukaemia cell count. Leukapheresis can be used prior to chemotherapy in the interim. Before returning the remaining blood to the patient, the procedure known as "leukapheresis" involves taking the patient's blood and passing it through a machine to remove white blood cells, particularly those associated with leukaemia. It is necessary to have two intravenous (IV) lines; one is used to draw blood, the other is used to send it through the machine and return the blood to the patient. This therapy significantly reduces blood counts. Although the effect is transient, it might be beneficial until the chemotherapy has an opportunity to take action. Occasionally, a single large catheter is placed under the collarbone or in a tone in the neck for pheresis rather than using IV lines in both arms. Central venous catheters are referred to as CVCs[10].

Initiation of the treatment

This first step of treatment tries to immediately destroy as many leukaemia cells as feasible. The age and health of the patient determine how severe the treatment should be. Patients under 60 years old typically receive the most intense chemotherapy from Croakers, however some healthy older patients may benefit from considerably less rigorous treatment. Harsh chemotherapy may not be beneficial for elderly or sick people. This section deals with the treatment of these people. When selecting the treatment plan, account should be taken of other factors. Patients with leukaemia cells, for instance, who have particular gene or chromosome abnormalities, are more likely to respond well to particular treatment modalities[11],[12]. In younger cases, including those under 60, induction usually involves two chemotherapeutic medications. An anthracycline medication akin to idarubicin or daunorubicin (daunomycin) is called cytarabine (ara-C). It is usually referred to as a 7+3 system because it involves continuous administration of cytarabine in seven days, followed by small infusions of anthracycline for the next three days. A third medication may occasionally be used to increase the likelihood of absolution[13]. In addition to chemotherapy, a targeted therapeutic medication such as midostaurin (Rydapt) or quizartinib (Vanflyta) may be administered to individuals whose leukaemia cells exhibit a FLT3 gene mutation. Patients with leukaemia cells that carry the CD33 protein may benefit from adding gemtuzumab ozogamicin (Mylotarg), a targeted drug, to their chemotherapy regimen. Cladribine may be added to a patient's chemotherapy regimen in some cases. Individuals with compromised cardiac function might not respond well to anthracycline treatment; instead, they might benefit from fludarabine or etoposide, two alternative chemotherapy drugs[14],[15],[16]. Chemotherapy can be administered to cerebrospinal fluid in rare cases where leukaemia has spread to the brain or spinal cord[17]. Radiation therapy may also be performed. Individuals must frequently remain in the sanitarium for the duration of induction and sometimes even longer after. Leukaemia cells and most normal bone graft cells are eliminated during induction, which can lead to dangerously low blood counts and even fatal conditions. Antibiotics and blood products transfusions are necessary for most patients. Growth factors, or medications that raise white blood cell numbers, can also be applied. Low blood counts typically persist for a few weeks[18]. A bone gist vivisection will be performed by the croaker around a week after the procedure. Leukaemia must show a high concentration of hypocellular bone gist cells and a low proportion of blasts (no more than 5% of the bone gist) in order to be considered in absolution. The majority of leukaemia patients pass away after their first chemotherapy treatment. A second vivisection may be carried out in a week if it is uncertain whether the leukaemia is still present following the bone graft vivisection. Normal bone graft cells will regrow and start generating new blood cells over the course of the following few weeks. During this time, the croaker might conduct more bone gist necropsies. The croaker will examine cells in a bone marrow sample to evaluate if the leukaemia has resolved once the blood cell counts stabilise. Not all leukaemia cells are eliminated via absolution induction; others usually survive. In the absence of post-remission therapy (link), the leukaemia is probably going to come back in a few months[19].

Combination of treatments

For patients under 60, the major possibilities for connection treatment are:

• Chemotherapy with high-dose cytarabine (ara-C), also known as HiDAC.

• An allogeneic (patron) stem cell transplant.

• An autologous stem cell transplant. The stylish option for each person is determined by the risk of leukaemia recurrence following therapy, among other variables.

Connection to people who are older or have other medical problems. Severe connection therapy may not be tolerated by older people or those in poor health. Giving them more severe therapy frequently increases the risk of serious side effects (including death) while providing no additional benefit. The methods of treatment may be as follows for these individuals:

• Cytarabine used in advanced treatment is typically not as high as it is in younger patients.

• Standard- cure cytarabine, perhaps combined with idarubicin, daunorubicin, or mitoxantrone. In most cases, patients receiving targeted medicinal products during induction, such as quizartinib or midostaurin, continue to receive them during treatment.

• A mini-transplant is a non-myeloablative stem cell transplant[20],[21].

Maintenance

Conservation methods could be an option for further treatment. Treatment is administered over a longer period of time and often at lower doses during the stage. It's designed to prevent the leukaemia from returning as much as possible. There's no need for a conservation remedy for everyone with AML. However, in some cases where a person has an increased risk of leukaemia returning or is not able to proceed with the initial treatment for whatever reason, this might be considered[22]. For some people whose AML goes into absolution after induction or indeed after connection, conservation treatment with the oral chemo medicine azacitidine might be an option. Continuation of the targeted medicinal product without chemotherapy may be an option for patients who have entered the targeted medicinal product as part of their initial treatment[23].

Figure 2. Describes the mechanism of the treatment.



Handling Elderly or Physically Weak Patients

Treatment for AML in persons under the age of 60 is quite common. It requires cycles of harsh chemotherapy, which is frequently supplemented with targeted medication or a stem cell transplant (as previously stated). Many people over the age of 60 are healthy enough to be treated in the same way, albeit the chemotherapy may be less intensive. This intensive treatment may not be tolerated by people who are much older or with poor health. In fact, severe chemotherapy may shorten their lives. Treatment for these people is rarely divided into phases, but it can be given as needed. Older persons or those in poor health might have the following options: Low-intensity chemotherapy with medications such as low-dose cytarabine (LDAC), azacitidine (Vidaza), or decitabine (Dacogen)[24],[25],[26],[27].

Figure 3. Graph for different kinds of risk factors and patient handling.



Conclusion

AML treatment is rapidly evolving, adopting a variety of techniques. Treatment approaches must be tailored to clinical considerations as well as AML's unique molecular characteristics. Personalised techniques have the potential to improve treatment outcomes while maximising efficacy. Acute myeloid leukaemia is commonly seen throughout the bone marrow, however it can potentially spread to other organs[28],[29]. However, unlike other malignancies, it rarely causes tumours. Because of this, AML cannot be staged in the same way that other malignancies are. Precision medicine has transformed the diagnosis and treatment of acute myeloid leukaemia (AML), moving away from standardised chemotherapy regimens and towards individualised methods based on molecular and genetic profiles and targeted therapy. Acute myeloid leukaemia (AML) is the most often diagnosed leukaemia. In elderly folks, AML has a negative consequence. AML begins with a dominant mutation and progresses to collaborative transformational mutations, which result in myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is began quickly, making it impossible to examine the mutational profile of a patient's leukaemia when making treatment options[30],[31].

References

1. Döhner, H., Wei, A.H. and Löwenberg, B., 2021. Towards precision medicine for AML. Nature reviews Clinical oncology, 18(9), pp.577-590.
2. Burd, A., Levine, R.L., Ruppert, A.S., Mims, A.S., Borate, U., Stein, E.M., Patel, P., Baer, M.R., Stock, W., Deininger, M. and Blum, W., 2020. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature medicine, 26(12), pp.1852-1858.
3. Megías-Vericat, J.E., Martínez-Cuadrón, D., Solana-Altabella, A. and Montesinos, P., 2020. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. Expert Review of Hematology, 13(10), pp.1057-1065.
4. Marconi, G., Guolo, F., Nanni, J. and Papayannidis, C., 2023. Precision medicine for acute myeloid leukemia. Frontiers in Oncology, 13, p.1233757.
5. Collins, F.S. and Varmus, H., 2015. A new initiative on precision medicine. New England journal of medicine, 372(9), pp.793-795.
6. Guo, Y., Wang, W. and Sun, H., 2022. A systematic review and meta-analysis on the risk factors of acute myeloid leukemia. Translational Cancer Research, 11(4), p.796.
7. Albrecht, T.A., 2014, May. Physiologic and psychological symptoms experienced by adults with acute leukemia: an integrative literature review. In Oncology nursing forum (Vol. 41, No. 3, p. 286). NIH Public Access.
8. Estey, E. and Döhner, H., 2006. Acute myeloid leukaemia. The Lancet, 368(9550), pp.1894-1907.

9. Burnett, A.K., 2012. Treatment of acute myeloid leukemia: are we making progress?. Hematology 2010, the American Society of Hematology Education Program Book, 2012(1), pp.1-6.
10. Zhang, D., Zhu, Y., Jin, Y., Kaweme, N.M. and Dong, Y., 2021. Leukapheresis and hyperleukocytosis, Past and future. International Journal of General Medicine, pp.3457-3467.
11. Stubbins, R.J., Francis, A., Kuchenbauer, F. and Sanford, D., 2022. Management of acute myeloid leukemia: A review for general practitioners in oncology. Current Oncology, 29(9), pp.6245-6259.
12. O'Donnell, M.R., Tallman, M.S., Abboud, C.N., Altman, J.K., Appelbaum, F.R., Arber, D.A., Bhatt, V., Bixby, D., Blum, W., Coutre, S.E. and De Lima, M., 2017. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 15(7), pp.926-957.
13. Tefferi, A. and Letendre, L., 2012. Going beyond 7+ 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol, 30(20), pp.2425-2428.
14. Totiger, T.M., Ghoshal, A., Zabroski, J., Sondhi, A., Bucha, S., Jahn, J., Feng, Y. and Taylor, J., 2023. Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines, 11(2), p.641.
15. Grunwald, M.R. and Levis, M.J., 2013. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. International journal of hematology, 97, pp.683-694.
16. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18:1061-1075.
17. Cooper, G. and Adams, K., 2022. The cell: a molecular approach. Oxford University Press.
18. Patel, N., RIch, B.J., Patel, S., Watts, J.M., Benveniste, R., Abramowitz, M., Markoe, A., Eichberg, D.G., Komotar, R.J., De La Fuente, M. and Pasol, J., 2021. Emergent radiotherapy for leukemia-induced cranial neuropathies refractory to intrathecal therapy. Cureus, 13(5).
19. Bär, I., Ast, V., Meyer, D., König, R., Rauner, M., Hofbauer, L.C. and Müller, J.P., 2020. Aberrant bone homeostasis in AML is associated with activated oncogenic FLT3-dependent cytokine networks. Cells, 9(11), p.2443.
20. Nair, R., Salinas-Illarena, A. and Baldauf, H.M., 2021. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia, 35(2), pp.299-311.
21. Ungewickell, A. and Medeiros, B.C., 2012. Novel agents in acute myeloid leukemia. International journal of hematology, 96, pp.178-185.
22. Reville, P.K. and Kadia, T.M., 2021. Maintenance therapy in AML. Frontiers in Oncology, 10, p.619085.
23. Senapati, J., Kadia, T.M. and Ravandi, F., 2023. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica, 108(9), p.2289.
24. Finn, L., Dalovisio, A. and Foran, J., 2017. Older patients with acute myeloid leukemia: treatment challenges and future directions. Ochsner Journal, 17(4), pp.398-404.
25. Palmieri, R., Paterno, G., De Bellis, E., Mercante, L., Buzzatti, E., Esposito, F., Del Principe, M.I., Maurillo, L., Buccisano, F. and Venditti, A., 2020. Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness. Cancers, 12(1), p.120.
26. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.
27. Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., Büchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A. and Levine, R.L., 2017. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, The Journal of the American Society of Hematology, 129(4), pp.424-447.
28. Khan, M., Mansoor, A.E.R. and Kadia, T.M., 2017. Future prospects of therapeutic clinical trials in acute myeloid leukemia. Future Oncology, 13(6), pp.523-535.
29. Kantarjian, H., 2016. Acute myeloid leukemia--major progress over four decades and glimpses into the future. American Journal of Hematology, 91(1), pp.131-145.
30. Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M. and Ravandi, F., 2021. Acute myeloid leukemia: current progress and future directions. Blood cancer journal, 11(2), p.41.
31. Short, N.J. and Ravandi, F., 2016. Acute myeloid leukemia: past, present, and prospects for the future. Clinical Lymphoma Myeloma and Leukemia, 16, pp.S25-S29.